Orelabrutinib
- Generic Name
- Orelabrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25N3O3
- CAS Number
- 1655504-04-3
- Unique Ingredient Identifier
- WJA5UO9E10
- Background
Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
- Indication
⑴既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。
⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus, SLE
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT05688696
- Locations
- 🇨🇳
Jilin Provincial People's Hospital, Changchun, Jilin, China
🇨🇳Daqing Oilfield General Hospital, Daqing, Heilongjiang, China
🇨🇳Yiyang Central Hospital, Yiyang, Hunan, China
Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05684653
- Locations
- 🇨🇳
The First Affilitaed Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affilitaed Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Shulan (Hangzhou) hospital, Hangzhou, Zhejiang, China
Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
- Conditions
- Healthy Subject
- Interventions
- Drug: Placebo (orelabrutinib tablet simulator)
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05660720
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, China
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 28
- Registration Number
- NCT05600660
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 46
- Registration Number
- NCT05498259
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05495828
- Locations
- 🇨🇳
Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing, China
A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05491044
- Locations
- 🇨🇳
Department of Hematology, Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05390749
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Sanbo Brain Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing TianTan Hospital, Beijing, Beijing, China
Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 77
- Registration Number
- NCT05381506
- Locations
- 🇨🇳
West China Hospital.Sichuan University, Chengdu, Sichuan, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Guangxi Medical University Cancer Hospital, Naning, Guangxi, China
Genotype-guided Treatment in DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1100
- Registration Number
- NCT05351346
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.